Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy ; volume:13 ; number:1 ; day:24 ; month:10 ; year:2014 ; pages:1-16 ; date:12.2014
Molecular cancer ; 13, Heft 1 (24.10.2014), 1-16, 12.2014
- Creator
-
Iida, Mari
Brand, Toni M.
Starr, Megan M.
Huppert, Evan J.
Luthar, Neha
Bahrar, Harsh
Coan, John P.
Pearson, Hannah E.
Salgia, Ravi
Wheeler, Deric L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-13-242
- URN
-
urn:nbn:de:101:1-2019102719422206570684
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Iida, Mari
- Brand, Toni M.
- Starr, Megan M.
- Huppert, Evan J.
- Luthar, Neha
- Bahrar, Harsh
- Coan, John P.
- Pearson, Hannah E.
- Salgia, Ravi
- Wheeler, Deric L.
- SpringerLink (Online service)
Other Objects (12)
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells